Beam Therapeutics Overview
Beam Therapeutics Target Price
See Beam Therapeutics's analyst price targets ($60) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$25.52
Average Target Price
$59.50
133.2% upside
133.2% upside2 analysts in the last 4 months
High: $80 | Low: $39
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-21 | H.C. WainwrightPatrick Trucchio | $80 | 213.5% upside |  |
| 2026-05-13 | Tudor PickeringWilliam Pickering | $39 | 52.8% upside | |
| 2026-02-25 | RBC Capital | $26 | 1.9% upside | |
| 2026-02-20 | Canaccord Genuity | $74 | 190% upside | |
| 2026-01-21 | Tudor PickeringWilliam Pickering | $41 | 60.7% upside | |
| 2026-01-20 | Bernstein | $41 | 60.7% upside | |
| 2026-01-07 | UBSMichael Yee | $28 | 9.7% upside | |
| 2025-11-24 | Evercore ISI | $35 | 37.1% upside | |
| 2025-10-09 | Jefferies | $41 | 60.7% upside | |
| 2025-05-07 | GuggenheimDebjit Chattopadhyay | $55 | 115.5% upside | |
| 2025-03-03 | Scotiabank | $25 |  2% downside | |
| 2025-01-07 | Tudor PickeringWilliam Pickering | $37 | 45% upside | |
| 2024-11-06 | Leerink PartnersRick Bienkowski | $39 | 52.8% upside | |
| 2024-11-05 | BMO CapitalKostas Biliouris | $57 | 123.4% upside | |
| 2024-09-11 | Stifel NicolausBenjamin Burnett | $69 | 170.4% upside | |
| 2023-02-01 | Cantor Fitzgerald | $62 | 142.9% upside | |
| 2022-12-20 | BMO CapitalKostas Biliouris | $66 | 158.6% upside | |
| 2022-12-13 | Citigroup | $62 | 142.9% upside | |
| 2022-04-28 | Credit Suisse | $62 | 142.9% upside | |